BiotechTube

Serlopitant + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pruritus

Conditions

Pruritus, Burns

Trial Timeline

Nov 1, 2016 → Jan 17, 2017

NCT ID
NCT02975271

About Serlopitant + Placebo

Serlopitant + Placebo is a phase 2 stage product being developed by Vyne Therapeutics for Pruritus. The current trial status is terminated. This product is registered under clinical trial identifier NCT02975271. Target conditions include Pruritus, Burns.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02975271Phase 2Terminated
NCT02196324Phase 2Completed

Competing Products

20 competing products in Pruritus

See all competitors
ProductCompanyStageHype Score
Nalmefene + PlaceboTharimmunePhase 2
44
SHR0410Jiangsu Hengrui MedicinePhase 1
33
SHR0410 + PlaceboJiangsu Hengrui MedicinePhase 1
33
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mgNovartisPhase 2
52
MR13A9 + PlaceboKissei PharmaceuticalPhase 3
76
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
51
GabapentinPfizerPre-clinical
22
Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
76
BLU-5937 + PlaceboGSK plcPhase 2
51
Dupilumab 300Mg Solution for InjectionRegeneron PharmaceuticalsPhase 2
51
REGN846Regeneron PharmaceuticalsPhase 1/2
40
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 2
49
Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kgHaisco Pharmaceutical GroupPhase 2
49
HSK21542 tablet + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
74
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
28
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60
VLY-686 + PlaceboVanda PharmaceuticalsPhase 2
44
VLY-686 + PlaceboVanda PharmaceuticalsPhase 1
25

Other Products from Vyne Therapeutics

Isotretinoin + Amzeeq 4% Topical FoamApproved
77
FMX103 minocycline foam 1.5% + Vehicle foamPhase 3
69
5 mg Serlopitant TabletsPhase 3
69
5mg Serlopitant Tablets + Placebo TabletsPhase 3
69
FMX-101, 4% minocycline foam + Vehicle FoamPhase 3
69